Effectiveness and safety of orelabrutinib combined with rituximab, temozolomide, methotrexate, and cytarabine in intensive chemotherapy-unfit patients with PCNSL in China
The ORT-M/A chemotherapy regimen was efficacious and well-tolerated in our patients with PCNSL. This retrospective study provided a potential therapeutic strategy for PCNSL patients who are unfit for intensive chemotherapy and warrant further investigation.
Authors
- Zhengzhi Zou (ORCID: https://orcid.org/0000-0002-1893-7649)
- Jin Gong (ORCID: https://orcid.org/0000-0002-0059-8087)
- Jia Liu (ORCID: https://orcid.org/0000-0001-8413-6308)
- Xiaonan Wang (ORCID: https://orcid.org/0000-0001-9775-2417)
- Fenfen He
- Lingling Liu (ORCID: https://orcid.org/0009-0002-9468-015X)
- Jiajun Liu (ORCID: https://orcid.org/0009-0001-5991-7388)
- Chaofeng Liang (ORCID: https://orcid.org/0000-0002-4676-5899)
- Zhigang Fang (ORCID: https://orcid.org/0000-0002-6380-0246)
- Hongyan Ling
Institutions
- Sun Yat-sen University (CN)
- South China Normal University (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1186/s40001-025-03657-2
- Citations
- 1
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.39